rucaparib (Rubraca) accepted for restricted use within NHSScotland

SMC has accepted rucaparib as monotherapy for maintenance of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy. Use is restricted to patients without BRCA mutation.

SPS commentary:

Separately, NICE (TA611) had also approved use of rucaparib for this indication within the Cancer Drugs Fund.


NHS Scotland

Resource links:

ICE TA611 (November 2019)